A large spend figure does not tell you which decision to make.

NHSBSA's Secondary Care Medicines Dataset contains stock-control issues and an indicative price measure (NHSBSA, n.d.). That measure can differ substantially from actual net cost. This distinction matters before any comparison is drawn. Issued stock is not the same as administrations to patients, and an indicative value is not a trust's confidential acquisition price. A proposed analysis would display the data definition beside the finding and identify which questions require locally authorised information that the public dataset cannot supply.

A meaningful local review may need to include administration, monitoring, pharmacy preparation, service capacity and the consequences of changing delivery. Decide which costs belong within the comparison and which cannot yet be estimated. Separate observed information from scenarios. If an option changes the work required from another team, include that work rather than treating it as free capacity. The objective is a transparent organisational comparison that specialists and finance colleagues can examine, not a ranking based on incomplete public prices.

Separate changes in activity, treatment mix, unit acquisition cost and delivery cost when examining a local expenditure change. A larger total may reflect more people accessing an appropriate service, rather than poor purchasing or avoidable waste. The available data may not support a complete decomposition; display the unresolved part explicitly. This helps a finance and clinical team ask a sharper question before a public trend is used to justify a local intervention.

A bounded PHARMORIS evaluation could compare the team's usual preparation of a high-cost medicines review with a source-linked draft based on the same permitted materials. Inputs would include the decision question, applicable guidance, authorised aggregate activity and explicit resource assumptions. Independent clinical, pharmacy and finance reviewers would assess the draft. The initial task would not approve treatment, determine individual eligibility or adjudicate commissioner disputes. It would test whether preparing a coherent local case becomes more accurate or less burdensome.

Stop if a draft treats public indicative cost as net expenditure, uses stock issues as a count of treated people or confuses commissioner responsibility with funding entitlement. Agree additional quality and effort thresholds before comparison begins. If the case cannot be resolved without unavailable contractual information, the correct output is a clear data requirement. That can still be valuable. It helps the organisation decide whether further diligence is worth pursuing and prevents premature confidence from shaping an expensive investment or service decision.

A high-cost medicines pharmacist, service lead, commissioning representative and finance reviewer can define the decision and the information available to support it. We can discuss whether a bounded preparation comparison would be useful. The commercial opportunity is a repeatable, credible way to connect evidence with an organisational decision. PHARMORIS is a development programme, and this proposed use case needs evaluation. It does not imply current deployment, commissioned access to restricted datasets or a demonstrated reduction in medicines expenditure.